1999
Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial
Heier J, Cheetham J, DeGryse R, Dirks M, Caldwell D, Silverstone D, Rosenthal A. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. American Journal Of Ophthalmology 1999, 127: 253-259. PMID: 10088733, DOI: 10.1016/s0002-9394(98)00413-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnterior ChamberAnti-Inflammatory Agents, Non-SteroidalDouble-Blind MethodFemaleHumansKetorolac TromethamineLens Implantation, IntraocularMaleMiddle AgedOphthalmic SolutionsPain, PostoperativePhacoemulsificationSafetyTolmetinTreatment OutcomeTromethamineUveitis, AnteriorConceptsSevere anterior segment inflammationAnterior segment inflammationIntraocular lens implantationCataract surgeryVehicle solutionOphthalmic solutionLens implantationSubstantial anti-inflammatory activityVehicle-controlled clinical trialSafety of ketorolacAnterior chamber cellsParallel-group studyEye four timesUnilateral cataract surgerySevere ocular inflammationLack of efficacyAnti-inflammatory activityCiliary flushKetorolac groupTopical ketorolacAdverse eventsOcular inflammationOnly patientsVisual acuityIntraocular pressure
1991
Evaluation of Once-Daily Levobunolol 0.25% and Timolol 0.25% Therapy for Increased Intraocular Pressure
Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, Kelley E, Lue J. Evaluation of Once-Daily Levobunolol 0.25% and Timolol 0.25% Therapy for Increased Intraocular Pressure. American Journal Of Ophthalmology 1991, 112: 56-60. PMID: 1882923, DOI: 10.1016/s0002-9394(14)76213-0.Peer-Reviewed Original ResearchConceptsOpen-angle glaucomaLevobunolol groupTimolol groupOcular hypertensionIntraocular pressureThree-month study periodIncreased Intraocular PressureOcular hypotensive efficacyOverall mean decreaseMean heart rateHypotensive efficacyBlood pressureClinical trialsHeart rateMean decreaseTreatment groupsThree monthsPatientsStudy periodHypertensionGlaucomaGroupLevobunololTimololTherapy
1989
Effect of varying drop size on the efficacy and safety of a topical beta blocker.
Charap A, Shin D, Petursson G, Cinotti D, Wortham E, Brown R, Silverstone D, Atkins J, Eto C, Lue J. Effect of varying drop size on the efficacy and safety of a topical beta blocker. Annals Of Ophthalmology - Glaucoma 1989, 21: 351-7. PMID: 2683937.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdultBlood PressureDosage FormsDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyExercise TestFollow-Up StudiesGlaucoma, Open-AngleHeart RateHumansIntraocular PressureLevobunololMiddle AgedMulticenter Studies as TopicRandom AllocationTime FactorsVisual AcuityConceptsIntraocular pressureBeta blockersHeart rateMicroL of vehicleTopical beta blockersMean intraocular pressureElevated intraocular pressureMean heart rateLevobunolol 0.5Levobunolol groupBlood pressureAcute studyTopical solutionVehicle groupChronic studiesMean decreaseControl groupOne hourEfficacyLevobunololBlockersSafetyGroupMicroLPatients
1985
Levobunolol A Beta-adrenoceptor Antagonist Effective in the Long-term Treatment of Glaucoma
Group T, Berson F, Epstein D, Partamian L, Cinotti A, Cohen H, Fries P, David R, Gurion B, Duzman E, Novack G, Lue J, Foerster R, Galin M, Lass J, Ober M, Scharrer A, Shin D, Silverstone D. Levobunolol A Beta-adrenoceptor Antagonist Effective in the Long-term Treatment of Glaucoma. Ophthalmology 1985, 92: 1271-1276. PMID: 2865710, DOI: 10.1016/s0161-6420(85)33887-3.Peer-Reviewed Original ResearchConceptsLong-term treatmentDouble-masked studyOcular hypotensive efficacyOcular hypotensive effectOpen-angle glaucomaMean heart rateConcentrations of levobunololTest medicationOcular hypertensionBlood pressureMean IOPSystemic reactionsOcular safetyEffective therapyHeart rateOphthalmic solutionGlaucomaLevobunololPatientsTwo-year periodTimololTreatmentHypertensionMedicationsIOP